 CAMBRIDGE, Mass., Sept. 16, 2021 GLOBE NEWSWIRE -- Intellia Therapeutics, Inc. NASDAQ:NTLA, a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPRCas9 technology both in vivo and ex vivo, today announced that the U.S. Food and Drug Administration FDA has accepted the investigational new drug IND application for NTLA-5001, the companys first wholly-owned ex vivo CRISPR genome editing candidate for the treatment of cancer. NTLA-5001 is an autologous T cell receptor TCR-T cell therapy engineered to target the Wilms Tumor WT1 antigen for the treatment of all genetic subtypes of acute myeloid leukemia AML. Intellia intends to initiate patient screening by year-end in a Phase 12a study evaluating NTLA-5001 in adults with persistent or recurrent AML who have previously received first-line therapy. 